ATE211921T1 - Verwendung von gonadotropin zur behandlung der gestartigen hypertrophie der prostata - Google Patents

Verwendung von gonadotropin zur behandlung der gestartigen hypertrophie der prostata

Info

Publication number
ATE211921T1
ATE211921T1 AT96937823T AT96937823T ATE211921T1 AT E211921 T1 ATE211921 T1 AT E211921T1 AT 96937823 T AT96937823 T AT 96937823T AT 96937823 T AT96937823 T AT 96937823T AT E211921 T1 ATE211921 T1 AT E211921T1
Authority
AT
Austria
Prior art keywords
gonadotropin
treatment
benign prostatic
prostatic hypertrophy
prostate hypertrophy
Prior art date
Application number
AT96937823T
Other languages
English (en)
Inventor
John Mcmichael
Original Assignee
Milkhaus Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Milkhaus Lab Inc filed Critical Milkhaus Lab Inc
Application granted granted Critical
Publication of ATE211921T1 publication Critical patent/ATE211921T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT96937823T 1996-01-30 1996-10-30 Verwendung von gonadotropin zur behandlung der gestartigen hypertrophie der prostata ATE211921T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/593,501 US5610136A (en) 1996-01-30 1996-01-30 Method for treatment of benign prostatic hypertrophy
PCT/US1996/017421 WO1997027869A1 (en) 1996-01-30 1996-10-30 Method for treatment of benign prostatic hypertrophy

Publications (1)

Publication Number Publication Date
ATE211921T1 true ATE211921T1 (de) 2002-02-15

Family

ID=24374964

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96937823T ATE211921T1 (de) 1996-01-30 1996-10-30 Verwendung von gonadotropin zur behandlung der gestartigen hypertrophie der prostata

Country Status (8)

Country Link
US (1) US5610136A (de)
EP (1) EP0817645B1 (de)
JP (1) JP2971950B2 (de)
AT (1) ATE211921T1 (de)
AU (1) AU705524B2 (de)
CA (1) CA2216810C (de)
DE (1) DE69618578T2 (de)
WO (1) WO1997027869A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319504B1 (en) 1996-06-24 2001-11-20 University Of Maryland Biotechnology Institute Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
US6583109B1 (en) 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
US7994278B1 (en) 1999-08-06 2011-08-09 Nobel Biosciences Llc Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)
US7101847B2 (en) * 2002-10-11 2006-09-05 Milkhaus Laboratory, Inc. Method of treating chronic pelvic pain syndrome by administration of chorionic gonadotropin
ES2288641T3 (es) * 2002-12-20 2008-01-16 Dynogen Pharmaceuticals Inc. Metodo para tratar trastornos indoloros de la vejiga usando moduladores de canales del calcio de la subunidad alfa2-delta.
EP1721607A1 (de) * 2003-03-21 2006-11-15 Dynogen Pharmaceuticals, Inc. Verfahren zur Behandlung von Erkrankungen der unteren Harnwege mittels Modulatoren der glatten Muskulatur und Modulatoren der alpha-2-delta Untereinheit des Kalziumkanals
US7605122B2 (en) * 2005-07-29 2009-10-20 Millennium Medical Spa Human chorionic gonadotropin (hCG) formulations for facilitating weight loss and body contouring
WO2007035395A2 (en) * 2005-09-16 2007-03-29 Virginia Commonwealth University Intellectual Property Foundation Therapeutic compositions comprising chorionic gonadotropins and hmg coa reductase inhibitors
US9707403B2 (en) 2007-12-12 2017-07-18 Neuro Code Tech Holdings, Llc Rapid destruction of malignant tumors by excitotoxicity and osmotic-shock medical tactics
WO2009089517A1 (en) 2008-01-10 2009-07-16 The Neuro-Signaling Foundation Method and system for processing cancer cell electrical signals for medical therapy
EP2265326A4 (de) 2008-04-17 2011-06-22 Neuro Signaling Foundation System und verfahren zur auslösung einer apoptose in malignen tumorzellen zur medizinischen behandlung
AU2009292643B2 (en) 2008-09-19 2016-02-18 Nektar Therapeutics Polymer conjugates of therapeutic peptides
US11154238B2 (en) 2015-08-07 2021-10-26 Electroceuticals, Llc Systems, methods and apparatuses for providing bioelectronic neurocode-based therapies to mammals

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526716A (en) * 1981-11-20 1985-07-02 The Ohio State University Antigenic modification of polypeptides
US4384995A (en) * 1980-01-16 1983-05-24 The Ohio State University Antigenic modification of polypeptides
US4691006A (en) * 1983-03-04 1987-09-01 Ohio State University Antigenic modification of polypeptides
US4302386A (en) * 1978-08-25 1981-11-24 The Ohio State University Antigenic modification of polypeptides
US4201770A (en) * 1973-05-07 1980-05-06 The Ohio State University Antigenic modification of polypeptides
US4002738A (en) * 1975-05-30 1977-01-11 Abbott Laboratories Treatment of specified neoplasias
US4144031A (en) * 1976-04-19 1979-03-13 International Radioimmune Systems, Inc. Cell test for detecting human chorionic gonadotropin
US4116776A (en) * 1976-04-19 1978-09-26 International Radioimmune Systems, Inc. Diagnostic blood test and kit for detecting human chorionic gonadotropin
US4228127A (en) * 1978-10-06 1980-10-14 International Radioimmune Systems, Inc. Kit for detecting human chorionic gonadotropin
US4321260A (en) * 1980-05-22 1982-03-23 Ayerst, Mckenna & Harrison Inc. Method of using gonadorelin for the treatment of benign prostatic hyperplasia
US4692332A (en) * 1985-01-18 1987-09-08 Mcmichael John Immunotherapeutic methods and compositions employing antigens characteristic of malignant neoplasms

Also Published As

Publication number Publication date
DE69618578D1 (de) 2002-02-21
EP0817645A4 (de) 2000-11-29
CA2216810A1 (en) 1997-08-07
EP0817645A1 (de) 1998-01-14
EP0817645B1 (de) 2002-01-16
AU7527896A (en) 1997-08-22
WO1997027869A1 (en) 1997-08-07
US5610136A (en) 1997-03-11
JP2971950B2 (ja) 1999-11-08
JPH10507468A (ja) 1998-07-21
DE69618578T2 (de) 2003-01-23
CA2216810C (en) 2005-04-26
AU705524B2 (en) 1999-05-27

Similar Documents

Publication Publication Date Title
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE211921T1 (de) Verwendung von gonadotropin zur behandlung der gestartigen hypertrophie der prostata
EA200000220A1 (ru) Сочетание ингибитора тирозинкиназы и химической стерилизации для лечения рака предстательной железы
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE60023982D1 (de) System zur Behandlung von benigner Prostatahyperplasie
ATE313326T1 (de) VERWENDUNG VON CABERGOLIN ZUR BEHANDLUNG VON ßRESTLESS LEGS SYNDROMß
ATE242238T1 (de) Chinolin- und chinazolin-verbindungen von therapeutischem nutzen, insbesondere zur behandlung von gutartiger prostatahyperplasie
ATE207356T1 (de) Verwendung von tiagabin zur behandlung von schlafstörungen
ATE222489T1 (de) Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren
DE69738045D1 (de) Verwendung von cetrorelix zur behandlung von benigne prostatahypertrophie und prostatakrebs
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
DE69814444D1 (de) Kombination von angiotensing-convertin-enzyme hemmern mit diuretikum zur behandlung von störungen der mikrozirkulation
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
ATE253061T1 (de) Zur behandlung von krebs nützliche thiophen- und furan-2,5-dicarboxamide
ATE156839T1 (de) Neue delta-17 und delta-20 ungesätigte und gesatigte 17--g(b)-substituierte-4-aza-5-g(a)- androstan-3-on verbindungen als inhibitoren von 5-alpha-reductase
NO994330L (no) Metode for behandling av en tumor
MY118986A (en) Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
ATE541565T1 (de) Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
ATE300295T1 (de) Verwendung von baclofen zur behandlung von alkoholismus
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
DE60313603D1 (de) Pharmazeutische kombination zur behandlung von benigner prostatahyperplasie oder zur langzeitvorbeugung von akuter harnzurückhaltung
NO20003848D0 (no) FremgangsmÕte ved behandling av folikkulært lymfom ved anvendelse av inhibitorer for lymfotoksin (LT)-veien
IT1293804B1 (it) Diarilalchilpiperazine attive sulle basse vie urinarie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties